BioXcel Therapeutics, Inc. Deferred Tax Liabilities, Gross
BioXcel Therapeutics, Inc. (BTAI) had Deferred Tax Liabilities, Gross of $2.60 million as of 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-27
- 2025-12-31: Deferred Tax Liabilities, Gross $2.60M.
- 2024-12-31: Deferred Tax Liabilities, Gross $600.00K.
- 2023-12-31: Deferred Tax Liabilities, Gross $197.00K.
- 2022-12-31: Deferred Tax Liabilities, Gross $256.00K.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $2.60M 10-K · filed 2026-03-27 |
| 2024-12-31 | $600.00K 10-K · filed 2026-03-27 |
| 2023-12-31 | $197.00K 10-K · filed 2025-03-28 |
| 2022-12-31 | $256.00K 10-K · filed 2024-03-22 |
| 2021-12-31 | $336.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $407.00K 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |